Citations

Clear

3942 citation(s) found for "To, Van".

Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients
Tefferi, Ayalew , Jimma, Thitina, Gangat, Naseema , Vaidya, Rakhee , Begna, Kebede H. , Hanson, Curtis A. , Dyke, Daniel L. Van , Caramazza, Domenica , Pardanani, Animesh

Mayo Clinic

Blood | September 1, 2011 | Volume: 118 | Issue: 17 | Pages: 4595-4598

10.1182/blood-2011-08-371096 | PMID 21881047 Get It

Abstract DIPSS-plus (the Dynamic International Prognostic Scoring System-plus) includes 8 risk factors for survival in primary myelofibrosis. In the present study of 884 karyotypically annotated patients with primary myelofibrosis, we sought to identify 1 or 2 parameters that can reliably predict death in the first 2 years of disease. After a median of 8.2 years from time of referral to the Mayo Clinic, 564 deaths (64% of patients in the study) had been recorded. Risk factors associated with > 80% 2-year mortality included monosomal karyotype, inv(3)/i(17q) abnormalities, or any 2 of the following: circulating blasts > 9%, leukocytes ≥ 40 × 109/L, or other unfavorable karyotype. Patients with any 1 of these risk profiles (n = 52) displayed significantly shorter overall survival than those otherwise belonging to a high-risk category per DIPSS-plus (n = 298); respective median survivals were 9 and 23 months (hazard ratio 2.2, 95% confidence interval 1.6-3.1; P < .01). The present information complements DIPSS-plus in the selection of primary myelofibrosis patients for high-risk treatment approaches.
Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone
Kumar, Shaji , Uno, Hajime , Jacobus, Susanna , Wier, Scott A. Van, Ahmann, Greg, Henderson, Kimberly J., Haug, Jessica, Greipp, Philip R., Fonseca, Rafaël , Rajkumar, S. Vincent , Callander, Natalie S. , Siegel, David S. , Rajkumar, S Vincent , Uno, Hajime , Fonseca, Rafael

Mayo Clinic

Blood | August 23, 2011 | Volume: 118 | Issue: 16 | Pages: 4359-4362

10.1182/blood-2011-03-342089 | PMID 21860025 Get It

Abstract Detection of specific chromosomal abnormalities by FISH and metaphase cytogenetics allows risk stratification in multiple myeloma; however, gene expression profiling (GEP) based signatures may enable more specific risk categorization. We examined the utility of 2 GEP-based risk stratification systems among patients undergoing initial therapy with lenalidomide in the context of a phase 3 trial. Among 45 patients studied at baseline, 7 (16%) and 10 (22%), respectively, were high-risk using the GEP70 and GEP15 signatures. The median overall survival for the GEP70 high-risk group was 19 months versus not reached for the rest (hazard ratio = 14.1). Although the medians were not reached, the GEP15 also predicted a poor outcome among the high-risk patients. The C-statistic for the GEP70, GEP15, and FISH based risk stratification systems was 0.74, 0.7, and 0.7, respectively. Here we demonstrate the prognostic value for GEP risk stratification in a group of patients primarily treated with novel agents. This trial was registered at www.clinicaltrials.gov as #NCT00098475.
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Zhu, Yuan Xiao , Braggio, Esteban , Shi, Chang-Xin, Bruins, Laura A., Schmidt, Jessica, Wier, Scott Van, Chang, Xiu-Bao, Bjorklund, Chad C. , Fonseca, Rafaël , Bergsagel, P. Leif , Orlowski, Robert Z. , Stewart, A. Keith, Orlowski, Robert Z. , Bergsagel, P. Leif , Braggio, Esteban , Fonseca, Rafael

Mayo Clinic

Blood | August 23, 2011 | Volume: 118 | Issue: 18 | Pages: 4771-4779

10.1182/blood-2011-05-356063 | PMID 21860026 Get It

Abstract The precise molecular mechanism of action and targets through which thalidomide and related immunomodulatory drugs (IMiDs) exert their antitumor effects remains unclear. We investigated the role of cereblon (CRBN), a primary teratogenic target of thalidomide, in the antimyeloma activity of IMiDs. CRBN depletion is initially cytotoxic to human myeloma cells, but surviving cells with stable CRBN depletion become highly resistant to both lenalidomide and pomalidomide, but not to the unrelated drugs bortezomib, dexamethasone, and melphalan. Acquired deletion of CRBN was found to be the primary genetic event differentiating isogenic MM1.S cell lines cultured to be sensitive or resistant to lenalidomide and pomalidomide. Gene expression changes induced by lenalidomide were dramatically suppressed in the presence of CRBN depletion, further demonstrating that CRBN is required for lenalidomide activity. Downstream targets of CRBN include interferon regulatory factor 4 (IRF4) previously reported to also be a target of lenalidomide. Patients exposed to, and putatively resistant to, lenalidomide had lower CRBN levels in paired samples before and after therapy. In summary, CRBN is an essential requirement for IMiD activity and a possible biomarker for the clinical assessment of antimyeloma efficacy.
Ran-dependent docking of importin-β to RanBP2/Nup358 filaments is essential for protein import and cell viability
Hamada, Masakazu , Haeger, Anna , Jeganathan, Karthik B. , Ree, Janine H. van, Malureanu, Liviu, Wälde, Sarah , Joseph, Jomon , Kehlenbach, Ralph H. , Deursen, Jan M. van , Jeganathan, Karthik B

Mayo Clinic

Journal of Cell Biology | August 22, 2011 | Volume: 194 | Issue: 4 | Pages: 597-612

10.1083/jcb.201102018 | PMID 21859863 Get It

RanBP2/Nup358, the major component of the cytoplasmic filaments of the nuclear pore complex (NPC), is essential for mouse embryogenesis and is implicated in both macromolecular transport and mitosis, but its specific molecular functions are unknown. Using RanBP2 conditional knockout mouse embryonic fibroblasts and a series of mutant constructs, we show that transport, rather than mitotic, functions of RanBP2 are required for cell viability. Cre-mediated RanBP2 inactivation caused cell death with defects in M9- and classical nuclear localization signal (cNLS)–mediated protein import, nuclear export signal–mediated protein export, and messenger ribonucleic acid export but no apparent mitotic failure. A short N-terminal RanBP2 fragment harboring the NPC-binding domain, three phenylalanine-glycine motifs, and one Ran-binding domain (RBD) corrected all transport defects and restored viability. Mutation of the RBD within this fragment caused lethality and perturbed binding to Ran guanosine triphosphate (GTP)–importin-β, accumulation of importin-β at nuclear pores, and cNLS-mediated protein import. These data suggest that a critical function of RanBP2 is to capture recycling RanGTP–importin-β complexes at cytoplasmic fibrils to allow for adequate cNLS-mediated cargo import.
Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium†
García‐Closas, Montserrat , Humphreys, Manjeet K., Platte, Radka, Hopper, John L. , Southey, Melissa C. , Apicella, Carmel, Hammet, Fleur, Schmidt, Marjanka K. , Tollenaar, Rob A.�E.�M. , Veer, Laura J. van’t , Fasching, Peter A. , Beckmann, Matthias W. , Ekici, Arif B. , Strick, Reiner , Peto, Julian , dos‐Santos‐Silva, Isabel , Fletcher, Olivia , Johnson, Nichola , Sawyer, Elinor J. , Tomlinson, Ian , Kerin, Michael J. , Burwinkel, Barbara , Marmé, F., Schneeweiß, Andreas , Sohn, Christof , Bojesen, Stig E. , Flyger, Henrik, Nordestgaard, Børge G. , Zamora, M. Pilar , Brenner, Hermann , Rahman, Nazneen , Turnbull, Clare , Seal, Sheila, Renwick, Anthony, Brauch, Hiltrud , Justenhoven, Christina , Brüning, Thomas , Network, The GENICA, Chang‐Claude, Jenny , Hein, Rebecca, Wang‐Gohrke, Shan , Dörk, Thilo , Schürmann, Peter , Bremer, Michael , Hillemanns, Peter , Nevanlinna, Heli , Heikkinen, Tuomas , Aittomäki, Kristiina, Blomqvist, Carl , Bogdanova, Natalia , Antonenkova, Natalia, Rogov, Yuriy , Karstens, Johann H., Bermisheva, Marina , Prokofieva, Darya, Gantcev, Shamil Hanafievich, Хуснутдинова, Э. К. , Lindblom, Annika , Margolin, Sara , Chenevix‐Trench, Georgia , Chen, Xiaoqing, Group, for the kConFab AOCS Management, Mannermaa, Arto, Kosma, Veli‐Matti , Soini, Ylermi, Kataja, Vesa , Lambrechts, Diether , Yesilyurt, Betül T., Chrisiaens, Marie-Rose, Peeters, Stéphanie , Radice, Paolo , Peterlongo, Paolo , Manoukian, Siranoush , Barile, Monica, Couch, Fergus, Diasio, Robert B. , Giles, Graham G. , Severi, Gianluca , Baglietto, Laura , Maclean, Catriona, Offit, Ken, Robson, Mark E. , Vijai, Joseph , Gaudet, Mia M., John, Esther M. , Winqvist, Robert , Pylkäs, Katri , Jukkola‐Vuorinen, Arja , Grip, Mervi, Andrulis, Irene L. , Knight, Julia A. , Mulligan, Anna Marie , O’Malley, Frances P., Brinton, Louise A. , Sherman, Mark E., Lissowska, Jolanta , Hooning, Maartje J. , Ouweland, Ans M.W. van den, Collée, J. Margriet, Czene, Kamila , Cox, Angela , Brock, Ian W., Reed, Malcolm , Cross, Simon S. , Dunning, Alison M. , Kang, Daehee , Yoo, Keun-Young, Noh, Dong‐Young , Ahn, Sei Hyun , Jakubowska, Anna , Lubiński, Jan , Jaworska, Katarzyna, Durda, Katarzyna, Sangrajrang, Suleeporn , Gaborieau, Valérie , Brennan, Paul , McKay, James , Shen, Chen‐Yang , Ding, Shian-ling, Hsu, Huan-Ming, Yu, Jyh-Cherng, Ashworth, Alan , Swerdlow, Anthony J. , Jones, Michael E. , Orr, Nick , Egan, Kathleen M. , Titus‐Ernstoff, Linda, Easton, Doug , Spurdle, Amanda B. , Webb, Penelope M. , DeFazio, Anna , Thorne, Heather , Lambrechts, Diether , Figueroa, Jonine D. , Broeks, Annegien , Benı́tez, Javier , Milne, Roger L. , Arias, José Ignacio , Müller, Heiko , Arndt, Volker , Network, The GENICA, Beesley, Jonathan , Chen, Xiaoqing, Group, for the kConFab AOCS Management, Mannermaa, Arto, Lee, Adam M. , Wang, Xianshu , Chanock, Stephen Jacob , Martens, John W.M. , Hall, Per N , Pharoah, Paul D.P. , Anton‐Culver, Hoda , Ziogas, Argyrios , Trentham‐Dietz, Amy , Newcomb, Polly A. , Fazio, Anna de , Nevanlinna, H , Dörk, Thilo , Lambrechts, Diether , Giles, Graham G , Peterlongo, Paolo , Spurdle, Amanda B , Webb, Penelope M , Hillemanns, Peter , Swerdlow, Anthony J , Radice, Paolo , Lissowska, Jolanta , John, Esther M , Joseph, Vijai , Southey, Melissa C , Dunning, Alison M , Jakubowska, Anna , Jones, Michael E , Lambrechts, Diether , Brenner, Hermann , Cox, Angela , García-Closas, Montserrat , Schmidt, Marjanka K , Severi, Gianluca , Ekici, Arif B , Bogdanova, Natalia V , Robson, Mark , Chenevix-Trench, Georgia , Czene, Kamila , Pylkäs, Katri , Manoukian, Siranoush , Lubinski, Jan , Baglietto, Laura , Fletcher, Olivia , Bojesen, Stig E , Brauch, Hiltrud , Lindblom, Annika , Sawyer, Elinor J , Orr, Nick , Kang, Daehee

Mayo Clinic

Human Molecular Genetics | August 18, 2011 | Volume: 20 | Issue: 23 | Pages: 4693-4706

10.1093/hmg/ddr368 | PMID 21852249 Get It

Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer
Stevens, Kristen N., Vachon, Celine M. , Slager, Susan, Lesnick, Timothy G. , Olswold, Curtis, Fasching, Peter A. , Miron, Penelope , Eccles, Diana , Carpenter, Jane, Winqvist, Robert , Brauch, Hiltrud , Schmidt, Marjanka K. , Cox, Angela , Cross, Simon S. , Sawyer, Elinor J. , Hartmann, Arndt, Beckmann, Matthias W. , Schulz-Wendtland, Rüdiger, Ekici, Arif B. , Tapper, William , Gerty, Susan M. , Durcan, Lorraine , Graham, Nikki , Hein, Rebecca, Nickels, Stephan, Flesch‐Janys, Dieter, Heinz, Judith , Sinn, Hans‐Peter , Konstantopoulou, Irene , Pectasides, Dimitrios , Dimopoulos, Athanasios M., Clarke, Christine L. , Balleine, Rosemary L. , Fredericksen, Zachary, Diasio, Robert B. , Ross, Eric A. , Weaver, JoEllen , Rüdiger, Thomas , Dünnebier, Thomas, Ademuyiwa, Foluso O. , Kulkarni, Swati , Pylkäs, Katri , Jukkola‐Vuorinen, Arja , Ko, Yon‐Dschun, Limbergen, Erik Van, Janssen, Hilde, Peto, Julian , Fletcher, Olivia , Giles, Graham G. , Baglietto, Laura , Verhoef, Senno, Tomlinson, Ian , Kosma, Veli‐Matti , Greco, Dario , Blomqvist, Carl , Irwanto, Astrid , Liu, Jianjun , Blows, Fiona M., Dawson, Sarah‐Jane , Margolin, Sara , Mannermaa, Arto, Martin, Nicholas G. , Montgomery, Grant W. , Lambrechts, Diether , dos‐Santos‐Silva, Isabel , Severi, Gianluca , Hamann, Ute, Easton, Douglas F., Chang‐Claude, Jenny , Yannoukakos, Drakoulis , Nevanlinna, Heli , Dimopoulos, Meletios Α. , Purrington, Kristen S. , Lambrechts, Diether , Vachon, Celine M. , Lee, Adam M. , Godwin, Andrew K. , Ambrosone, Christine B. , Fostira, Florentia , Dimopoulos, Athanasios M., Fountzilas, George , Olson, Janet E. , Pathak, Harsh B. , Försti, Asta , Beesley, Jonathan , Mannermaa, Arto, Pharoah, Paul D.P. , Wang, Xianshu , Couch, Fergus J. , Nevanlinna, H , Lambrechts, Diether , Giles, Graham G , Eccles, Diana , Dimopoulos, Meletios A , Konstantopoulou, Irene , Martin, Nicholas G , Sinn, Peter , Lambrechts, Diether , Cox, Angela , Schmidt, Marjanka K , Severi, Gianluca , Ekici, Arif B , Ademuyiwa, Foluso O , Pylkäs, Katri , Yannoukakos, Drakoulis , Baglietto, Laura , Fletcher, Olivia , Purrington, Kristen S , Brauch, Hiltrud , Sawyer, Elinor J , Liu, Jing

Mayo Clinic

Cancer Research | August 15, 2011 | Volume: 71 | Issue: 19 | Pages: 6240-6249

10.1158/0008-5472.can-11-1266 | PMID 21844186 Get It

Abstract Triple-negative breast cancers are an aggressive subtype of breast cancer with poor survival, but there remains little known about the etiologic factors that promote its initiation and development. Commonly inherited breast cancer risk factors identified through genome-wide association studies display heterogeneity of effect among breast cancer subtypes as defined by the status of estrogen and progesterone receptors. In the Triple Negative Breast Cancer Consortium (TNBCC), 22 common breast cancer susceptibility variants were investigated in 2,980 Caucasian women with triple-negative breast cancer and 4,978 healthy controls. We identified six single-nucleotide polymorphisms, including rs2046210 (ESR1), rs12662670 (ESR1), rs3803662 (TOX3), rs999737 (RAD51L1), rs8170 (19p13.1), and rs8100241 (19p13.1), significantly associated with the risk of triple-negative breast cancer. Together, our results provide convincing evidence of genetic susceptibility for triple-negative breast cancer. Cancer Res; 71(19); 6240–9. ©2011 AACR.
S1‐01‐02: Genome‐wide association studies using prospective cohorts: The CHARGE consortium
Fitzpatrick, Annette L., Younkin, Steven G., Wolf, Philip A. , Carrasquillo, Minerva M., DeStefano, Anita L. , Seshadri, Sudha , Ikram, M. Arfan , Guðnason, Vilmundur , Boada, Merçé , Williams, Julie , Amouyel, Philippe , Launer, Lenore J. , López, Oscar L. , Duijn, Cornelia M. van , Breteler, Monique M.B. , Lambert, Jean‐Charles , Harold, Denise , Ruiz, Agustı́n

Mayo Clinic

Alzheimer's & Dementia | August 1, 2011 | Volume: 7 | Issue: 4S_Part_2 | Pages: No page available

10.1016/j.jalz.2011.05.199 Get It

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers
Mattsson, Niklas , Andréasson, Ulf , Batish, Sat Dev, Bernardini, Sergio , Bocchio‐Chiavetto, Luisella , Blankenstein, Marinus A. , Carrillo, María C. , Chalbot, Sonia, Coart, Els, Chiasserini, Davide , Cutler, Neal E., Dahlfors, Gunilla, Duller, Stefan, Fagan, Anne M. , Frisoni, Giovanni B. , Galimberti, Daniela , Hampel, Harald , Handberg, Aase , Heneka, Michael T. , Herskovits, A. Zara , Herukka, Sanna‐Kaisa , Humpel, Christian , Iqbal, Khalid , Kaeser, Stephan A. , Kaiser, Elmar, Kapaki, Elisabeth, Kidd, Daniel, Klivènyi, Péter , Knudsen, Cindy Soendersoe, Kummer, Markus P. , Lui, James, Lladó, Albert , Li, Qiao‐Xin , Martins, Ralph N. , Masters, Colin L. , McAuliffe, John C., Mercken, Marc, Moghekar, Abhay , Molinuevo, José Luís , Montine, Thomas J. , Nowatzke, William, O’Brien, Richard , Otto, Markus , Parnetti, Lucilla , Petersen, Ronald C. , Prvulovic, David, Reus, Herman P.M. de, Scarpini, Elio , Stefani, Alessandro , Schröder, Johannes , Shaw, Leslie M. , Skinningsrud, Anders, Skrogstad, Brith, Spreer, Annette, Trojanowski, John Q. , Tumani, Hayrettin , Umek, Robert M., Broeck, Bianca Van, Vanderstichele, Hugo, Vécsei, László , Blennow, Kaj , Frisoni, Giovanni B. , Persson, Staffan , Arai, Hiroyuki N. , Forlenza, Orestes Vicente , Galasko, Douglas , Holtzman, David M. , Hyman, Bradley T. , Jucker, Mathias , Lewczuk, Piotr , Paraskevas, George P. , Rissman, Robert A. , Soininen, Hilkka S. , Talib, Leda Leme , Teunissen, Charlotte E. , Verbeek, Marcel M. , Windisch, Manfred , Zhang, Jing , Zetterberg, Henrik , Parnetti, Lucilla , Molinuevo, José Luis , Masters, Colin L , Otto, Markus , Galimberti, Daniela

Mayo Clinic

Alzheimer's & Dementia | July 25, 2011 | Volume: 7 | Issue: 4 | Pages: 386

10.1016/j.jalz.2011.05.2243 | PMID 21784349 Get It

BackgroundThe cerebrospinal fluid (CSF) biomarkers amyloid β (Aβ)‐42, total‐tau (T‐tau), and phosphorylated‐tau (P‐tau) demonstrate good diagnostic accuracy for Alzheimer's disease (AD). However, there are large variations in biomarker measurements between studies, and between and within laboratories. The Alzheimer's Association has initiated a global quality control program to estimate and monitor variability of measurements, quantify batch‐to‐batch assay variations, and identify sources of variability. In this article, we present the results from the first two rounds of the program.MethodsThe program is open for laboratories using commercially available kits for Aβ, T‐tau, or P‐tau. CSF samples (aliquots of pooled CSF) are sent for analysis several times a year from the Clinical Neurochemistry Laboratory at the Mölndal campus of the University of Gothenburg, Sweden. Each round consists of three quality control samples.ResultsForty laboratories participated. Twenty‐six used INNOTEST enzyme‐linked immunosorbent assay kits, 14 used Luminex xMAP with the INNO‐BIA AlzBio3 kit (both measure Aβ‐(1‐42), P‐tau(181P), and T‐tau), and 5 used Meso Scale Discovery with the Aβ triplex (AβN‐42, AβN‐40, and AβN‐38) or T‐tau kits. The total coefficients of variation between the laboratories were 13% to 36%. Five laboratories analyzed the samples six times on different occasions. Within‐laboratory precisions differed considerably between biomarkers within individual laboratories.ConclusionsMeasurements of CSF AD biomarkers show large between‐laboratory variability, likely caused by factors related to analytical procedures and the analytical kits. Standardization of laboratory procedures and efforts by kit vendors to increase kit performance might lower variability, and will likely increase the usefulness of CSF AD biomarkers.